ArticleHealthcare (Basel, Switzerland)2020
Risk Factors Associated with Recurrent
Article in Healthcare (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.International journal of clinical practice · 2022Pooled it
- Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Modeling Clostridioides difficile toxin pathogenesis and antiserum protection in an immunocompetent intestine-on-chip platform.Scientific reports · 2026Article
- Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection.BMC infectious diseases · 2026Article
- Invasive pericardial and pulmonary aspergillosis by uncommonFrontiers in medicine · 2026Article
- Burden ofAntibiotics (Basel, Switzerland) · 2025Article
- Healthcare-AssociatedMicroorganisms · 2025Article
- Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for RecurrentOpen forum infectious diseases · 2025Article
- Clostridioides difficile infection in Saudi Arabia: Prevalence, risk factors, and outcomes in a tertiary hospital setting.PloS one · 2025Article
- Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.Infectious diseases and therapy · 2024Article
- Observational
- Microbiota-Based Therapeutics as New Standard-of-Care Treatment for RecurrentVisceral medicine · 2024Review
- Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study.Infection · 2024Article
- Review of the Impact of Biofilm Formation on RecurrentMicroorganisms · 2023Review
- Article
- Review
- Post-DischargeInternational journal of environmental research and public health · 2022Observational
- Assessment of independent comorbidities and comorbidity measures in predicting healthcare facility-onset Clostridioides difficile infection in Kenya.PLOS global public health · 2022Article
- Effect of the Microbiome on Intestinal Innate Immune Development in Early Life and the Potential Strategy of Early Intervention.Frontiers in immunology · 2022Review
- Epidemiology of botulism in the north-western Romania-a 7-year survey.Environmental science and pollution research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.